48
Technology4h 23m ago

Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.

Archive Window: 7 Days Left

U.S.

Who
patients with early-stage TNBC
What
Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.
When
Fri, 12 Jun 2026 22:36:17 GMT · 4h 23m ago
Where
U.S. ·
Why
Emerging evidence suggests that the efficacy of immunotherapy (IO) may be influenced by the timing of drug administration, driven by circadian-regulated immune activity.
The Frontline Impact

How this affects you

A preliminary case series suggests that receiving immunotherapy infusions earlier in the day could lead to better outcomes for patients with early-stage triple-negative breast cancer, potentially reducing recurrence and improving pathological complete response rates. This observation, if validated by larger studies, could significantly alter current clinical scheduling practices for cancer treatments.

Story chain

2 events in this thread
  1. Technology4h 23m ago
    A preliminary case series suggested a potential association between late immunotherapy infusion timing and reduced pathological complete response (pCR) rates in early-stage Triple-Negative Breast Cancer (TNBC).
    Open article
  2. Currently Reading4h 23m ago
    Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.

Verified Sources & Citations